Cantargia Ab · OMXSTO:CANTA
Cantargia Ab — Redeye Investor Forum 2023
16 slides from Cantargia Ab's conference presentation, Mar 30, 2023
Slide 1: Targeting IL1RAP to address unmet needs in severe cancer and autoimmune diseases
Targeting IL1RAP to address unmet needs in severe cancer and autoimmune diseases Corporate Presentation Mar 2023 NASDAQ STOCKHOLM MAIN LIST (CANTA.ST)
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known and
Slide 3: New strategy to treat cancer supported by clinical results
New strategy to treat cancer supported by clinical results PROMISING DATA IN PANCREATIC CANCER → Stronger efficacy than expected from chemotherapy → Patients with higher IL1RAP benefit more Nadunolimab Durable response Primary Chemo- Short-term tumor therapy response Pancreas Resistant tumor SEVERAL
Slide 4: IL1RAP: Broad application in cancer and autoimmune disease
IL1RAP: Broad application in cancer and autoimmune disease 4
Slide 5: Nadunolimab clinical results
NADUNOLIMAB CLINICAL RESULTS
Slide 6: Positive interim data in 1st line pancreatic cancer
Positive interim data in 1st line pancreatic cancer Nadunolimab combination with Gem/Abraxane in 1st line (n=73): → 33% response rate with long PFS and OS → Additional 5 (7%) pts had on- treatment benefit beyond progression) → Promising PFS (7.2 mo), DCR (73%) and OS (12.7 mo1) → 12 pts still on tre
Slide 7: IL1RAP levels correlate with response – New results to be presented at AACR 2023
IL1RAP levels correlate with response – New results to be presented at AACR 2023 IL1RAP High Analysis of IL1RAP in pancreatic cancer biopsies and correlations to clinical efficacy: → Patients with highest IL1RAP levels benefitted most from nadunolimab and Gem/Abraxane → Full dataset to be presented
Slide 8: Combination strategy in NSCLC – Promising efficacy
Combination strategy in NSCLC – Promising efficacy Nadunolimab combination with Gem/Cis in 1st/2nd line: → 16 of 30 pts with objective response incl. 1 complete response (ORR 53%) (historical control data of 22-28%) → Generally well tolerated; neutropenia freq. higher than expected from chemo (manag
Slide 9: Promising early safety and efficacy in TNBC
Promising early safety and efficacy in TNBC Nadunolimab combination with Gem/Carbo in 100 % 1st/2nd line metastatic TNBC: Best change in tumor size 15 pts enrolled in the dose-escalation phase 50 % PD → Acceptable safety profile (G-CSF given prophylactically to control neutropenia) SD 0% → 12 pts tr
Slide 10: Key messages
Key messages → Most chemotherapies induce chemoresistance already after Resistant a few months of therapy. Chemotherapy can upregulate tumor both IL-1α and IL-1β. Chemo- therapy → Unlike other IL-1 blocking compounds, nadunolimab blocks both IL-1α and IL-1β signalling and improves chemotherapy effic
Slide 11: CAN10 – Opportunity in autoimmune/inflammatory disease
CAN10 – OPPORTUNITY IN AUTOIMMUNE/INFLAMMATORY DISEASE
Slide 12: CAN10 – Project status
CAN10 – Project status GLP toxicity study – Completed → CAN10 given i.v. once weekly for six weeks at doses up to 50 mg/kg or s.c. at 5 mg/kg → No adverse findings related to CAN10 at/above clinically relevant (pharmacologically active) dose levels Clinical phase I study – Study start planned for H1
Slide 13: Financials, milestones & summary
FINANCIALS, MILESTONES & SUMMARY
Slide 14: Several upcoming value inflection points
Several upcoming value inflection points Newsflow over next quarters Nadunolimab (CAN04) → Update of results for PDAC, NSCLC, TNBC and Keytruda combination → Start phase II/III Precision Promise℠ (PDAC) → New preclinical and translational results → New clinical data (efficacy and safety) → CAPAFOUR
Slide 15: Solid financial position with strong shareholder support
Solid financial position with strong shareholder support → Cash and cash equivalents SEK 427 M (~$41M) at end of Q4 2022 Current owners (Dec 31, 2022) → Runway until mid 2024 4th AP fund 8.8% Alecta 7.3% → Operating expenses SEK 382 M (~$37M) in 2022 → R&D - 96% of operating expenses Avanza Pension
Slide 16: Cantargia: Investment highlights
Cantargia: Investment highlights NOVEL IL1RAP ANTIBODIES, POTENTIAL TO ADDRESS CANCER & INFLAMMATORY DISEASE • IL1RAP elevated in most solid and liquid tumors • Potential to breakdown resistance to cancer treatment, enabled by unique dual action approach – nadunolimab • Additional key target for inf